FDA Panel Is a Win for Pfizer, Despite Mixed Result, Analyst Says

FDA Panel Is a Win for Pfizer, Despite Mixed Result, Analyst Says
·3 min read

SVB Leerink analyst Geoffrey Porges sees a silver lining from Pfizer's bumpy ride at a Food and Drug Administration advisory committee meeting about Covid-19 vaccine boosters.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting